A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Phase 2 Study to Evaluate the Efficacy and Safety of Oral BIIB061 as Add-On Therapy to Interferon-Beta 1 or Glatiramer Acetate Therapies in Relapsing Multiple Sclerosis
Overview
- Phase
- Phase 2
- Intervention
- BIIB061
- Conditions
- Relapsing Multiple Sclerosis
- Sponsor
- Biogen
- Primary Endpoint
- Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
- Status
- Withdrawn
- Last Updated
- 2 years ago
Overview
Brief Summary
The primary objectives of the study are to evaluate the safety of BIIB061 versus placebo in participants with Relapsing Multiple Sclerosis (RMS), and to evaluate the efficacy of BIIB061 to improve disability outcome versus placebo in participants with RMS.
The secondary objectives of the study are to evaluate the effects of BIIB061 versus placebo on brain magnetic resonance imaging (MRI) markers of remyelination and axon preservation in chronic Multiple Sclerosis lesions and to evaluate the effects of BIIB061 versus placebo on additional measures of improved disability outcome.
Detailed Description
BIIB061's unique mechanism of action may provide a pharmacological intervention to overcome the failure of remyelination in all forms of multiple sclerosis by blocking mechanisms that prevent differentiation of oligodendrocytes progenitors.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosed with relapsing-remitting multiple sclerosis (RRMS) or secondary progressive multiple sclerosis (SPMS)
- •Have a Baseline Expanded Disability Status Scale (EDSS) score of 2.0 to 6.0
- •Have a MS disease duration of ≤20 years from first MS symptom(s)
- •Must have at least one of the following occurring within 12 months prior to
- •Day 1/Baseline:
- •(a) ≥1 clinical relapse(s) or objective disability worsening (as per treating neurologist's judgment) (b) ≥1 Gadolinium (Gd)-enhancing T1 lesion(s) on brain or spinal cord Magnetic Resonance Imaging (MRI) (c) ≥1 new T2 lesion(s) on brain or spinal cord MRI (the reference scan used to detect new T2 lesion formation has to be ≤12 months prior to Day 1/Baseline)
- •Must have been taking one of the following disease-modifying therapy (DMTs) at a stable dose for at least 12 weeks prior to Day 1/Baseline:
- •Interferon-beta1 (IFN-β1): Avonex, Plegridy, Betaferon/Betaseron, Extavia, or Rebif
- •Glatiramer acetate (Copaxone or Glatopa).
Exclusion Criteria
- •A documented history of clinically significant persistent neutralizing antibody against IFN-β1 (applicable only for participants entering the study with IFN-β1 as a background DMT), in the opinion of the Investigator
- •Contraindications to MRI, for example, presence of pacemakers or other implanted metal devices (excluding dental braces), an allergy to Gd, renal impairment, or claustrophobia that cannot be medically managed
- •History or a positive test result at Screening for human immunodeficiency virus
- •Current hepatitis C infection (defined as positive hepatitis C virus \[HCV\] antibody and detectable HCV Ribonucleic acid (RNA)). Participants with positive HCV antibody and undetectable HCV RNA are eligible to participate in the study (United States \[US\] Centers for Disease Control and Prevention)
- •Current hepatitis B infection (defined as positive for hepatitis B surface antigen \[HBsAg\] or total hepatitis B core antibody \[anti-HBc\]). Participants with immunity to hepatitis B from previous natural infection (defined as negative HBsAg, positive anti-HBc, and positive hepatitis B surface antibody \[anti-HBs\]) or vaccination (defined as negative HBsAg, negative anti-HBc, and positive anti-HBs) are eligible to participate in the study
- •History of systemic hypersensitivity reaction to BIIB061
- •History of suicidal ideation or an episode of clinically severe depression (as determined by the Investigator) within 12 weeks of screening
- •Clinically significant (as determined by the Investigator) 12-lead ECG or laboratory assessment abnormalities
- •Any condition affecting study treatment absorption (e.g., gastrectomy)
- •Treatment with statins (3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors) or proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors (e.g., alirocumab and evolocumab) within 8 weeks prior to Day 1/Baseline
Arms & Interventions
BIIB061 Dose 1
Participants will receive BIIB061 Dose 1 orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
Intervention: BIIB061
Placebo
Participants will receive BIIB061-matched placebo, orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
Intervention: Placebo
Placebo
Participants will receive BIIB061-matched placebo, orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
Intervention: Interferon-beta1
Placebo
Participants will receive BIIB061-matched placebo, orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
Intervention: Glatiramer acetate
BIIB061 Dose 1
Participants will receive BIIB061 Dose 1 orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
Intervention: Interferon-beta1
BIIB061 Dose 1
Participants will receive BIIB061 Dose 1 orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
Intervention: Glatiramer acetate
BIIB061 Dose 2
Participants will receive BIIB061 Dose 2 orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
Intervention: BIIB061
BIIB061 Dose 2
Participants will receive BIIB061 Dose 2 orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
Intervention: Interferon-beta1
BIIB061 Dose 2
Participants will receive BIIB061 Dose 2 orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
Intervention: Glatiramer acetate
BIIB061 Dose 3
Participants will receive BIIB061 Dose 3 orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
Intervention: BIIB061
BIIB061 Dose 3
Participants will receive BIIB061 Dose 3 orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
Intervention: Interferon-beta1
BIIB061 Dose 3
Participants will receive BIIB061 Dose 3 orally once daily in addition to IFN-β1 injection or glatiramer acetate for up to 72 weeks.
Intervention: Glatiramer acetate
Outcomes
Primary Outcomes
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: First dose of study drug to end of the study (Up to Week 84)
An AE is any unfavorable and unintended sign (including an abnormal assessment such as an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Overall Disability Response Score (ODRS) at Week 48
Time Frame: Baseline, Week 48
ODRS is a multicomponent score based on 4 components: Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), 9-Hole Peg Test in the dominant hand (9HPT-D), and 9HPT in the nondominant hand (9HPT-ND). It assesses overall changes in disability over time. The 4 individual scores are added together to get the overall score that ranges from +4 to -4. At each visit, each component is given a score relative to baseline: -1 if threshold is met for worsening, 0 if no changes meet threshold criteria, or +1 if threshold is met for improvement. The thresholds for T25FW and 9HPT are defined by a 15% change from baseline (≥15% decrease from baseline for improvement and ≥15% increase from baseline for worsening). For EDSS, improvement is defined as a ≥1.0-point decrease in EDSS from a baseline score of ≤6.0, and worsening is defined as a ≥1-point increase from a baseline score of ≤5.5 or a ≥0.5-point increase from a baseline score equal to 6.0.
Secondary Outcomes
- ODRS Accounting Only for 12-week Confirmed Events of Worsening and Improvement on Respective Components over the First 48 Weeks of Treatment(48 weeks)
- Change from Baseline in Normalized Magnetization Transfer Ratio (nMTR) at Week 48(Baseline, Week 48)
- Change from Baseline in Diffusion Tensor Imaging Radial Diffusivity (DTI-RD) at Week 48(Baseline, Week 48)
- Change from Baseline in Normalized T1 (nT1) Intensity at Week 48(Baseline, Week 48)
- ODRS using 20% Threshold for T25FW over the First 48 Weeks of Treatment(48 weeks)
- Change from Baseline in T1 Hypointense Volume at Week 48(Baseline, Week 48)
- ODRS using 20% Threshold for T25FW, 9HPTD, and 9HPT-ND over the First 48 Weeks of Treatment(48 weeks)
- Percentage of Participants with 12-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, or 9HPT-ND(Up to Week 48)
- Percentage of Participants with 12-week Confirmed Worsening in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, or 9HPT-ND(Up to Week 48)